Retinalamin 5mg
A bovine-derived retinal polypeptide bioregulator investigated for ophthalmic neuroprotection in degenerative ocular models.
Mechanism
Binds AMPA, NMDA, and mGluR1 glutamate receptor subtypes to mitigate excitotoxicity and promote survival signaling in retinal ganglion cells and photoreceptors.
Dosing
The documented standard experimental regimen involves a whole-vial dose of 5 mg administered once daily for a 10-day cycle.
Reconstitution
Reconstituting a 5 mg vial with 1.0 mL of diluent yields an active concentration of 5 mg/mL.
Storage
Store lyophilized vials refrigerated between 2°C and 8°C away from light, and prepare solutions fresh prior to use.
Mix & measure Retinalamin 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Retinalamin 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 1.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Daily Administration (Days 1–10) | 5 mg once daily | 1.0 mL (100 units) |
| Maintenance / Follow-up (Months 3–6) | Repeat 10-day course | 1.0 mL (100 units) |
Reconstitution Steps
- 1
Decontaminate the rubber stoppers of the Retinalamin vial and diluent vial using fresh sterile alcohol pads, allowing them to fully air-dry.
- 2
Draw precisely 1.0 mL of bacteriostatic water or sterile saline using an appropriate sterile syringe.
- 3
Insert the needle at a slight angle and discharge the fluid gently against the internal glass wall to prevent foaming of delicate peptide fractions.
- 4
Carefully roll or swirl the vial between your palms until the lyophilizate fully clears; avoid vigorous shaking.
- 5
Visually inspect the dissolved solution to verify clarity and absence of particulate matter before immediate laboratory application.
Supplies Needed
Peptide Vial
Supplies 5 mg of lyophilized bovine retinal polypeptide complex for experimental application.
Insulin Syringes (U-100)
Employed to measure precise volume allocations or administer laboratory doses accurately.
Bacteriostatic Water
Serves as the sterile reconstitution solvent to dissolve the lyophilized peptide powder.
Alcohol Swabs
Utilized to clean and sanitize vial septums and tools to maintain strict sterile technique.
Why researchers study it
Retinal neuroprotection and cellular preservation
Mechanisms in primary open-angle glaucoma
Tissue support in diabetic retinopathy models
Glutamate receptor modulation in ocular cells
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Retinalamin is a biological cytomedine complex consisting of low-molecular-weight peptide fractions harvested from bovine retinal tissue. Originally developed and registered for clinical use in Russia and select CIS nations, it is classified as a tissue-specific peptide bioregulator intended to support retinal cellular health and neuroprotection. Unlike synthetic single-chain signaling peptides, Retinalamin is an organic biological extract containing a spectrum of peptide fragments that mirror the native composition of ocular structures. In experimental and clinical environments, the complex is primarily evaluated for its therapeutic potential in ocular conditions such as diabetic retinopathy, open-angle glaucoma, and general retinal degeneration. Researchers focus on how these extracted fractions may mitigate excitotoxic stress and preserve retinal ganglion cells and photoreceptor function. Despite its regulatory approval in regional Eastern European markets, the agent lacks approval from the FDA or EMA and has not been corroborated by Western double-blind randomized clinical trials. From a laboratory perspective, Retinalamin presents unique handling requirements due to its animal-derived natural origin. Batch uniformity is governed by strict extraction protocols rather than synthetic chemical synthesis. Investigational protocols evaluate its systemic biodistribution to ocular and cerebral tissues, typically utilizing whole-vial dosing regimens to study systemic retinal cellular responses.
References
- 1.Verlov et al., Vestnik Oftalmologii, 2021 — Ligand-receptor interaction and biodistribution of a drug containing cattle retinal polypeptides
- 2.Gabdrakhmanova et al., Vestnik Oftalmologii, 2018 — Molecular mechanisms of neuroretinoprotection in primary open-angle glaucoma
- 3.Malakhova et al., Vestnik Oftalmologii, 2024 — Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy
- 4.Dorofeev et al., Vestnik Oftalmologii, 2021 — Effect of retinal protective therapy on optical coherence tomography angiography (pilot study)
- 5.Kharintseva, Advances in Gerontology, 2011 — Retinoprotective therapy of diabetic macular edema in elderly patients
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allRetatrutide 30mg
Investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways to evaluate metabolic rate and body mass reduction.
View ProtocolRetatrutide 10mg
Experimental unimolecular triple agonist targeting GLP-1, GIP, and glucagon receptors for metabolic and adiposity research.
View ProtocolNAD+ 1000mg
Cellular coenzyme vital for mitochondrial bioenergetics, sirtuin activation, and systemic metabolic maintenance in research models.
View Protocol